Cagrilintide and semaglutide work through different mechanisms and have different dosing schedules: Cagrilintide: Amylin receptor agonist Escalation: 0.6 mg 1.2 mg 2.4 mg weekly Three-step titration over 8 weeks Semaglutide: GLP-1 receptor agonist Escalation: 0.25 mg 0.5 mg 1.0 mg 1.7 mg 2.4 mg weekly Five-step titration over 16-20 weeks When combined in CagriSema, both peptides are dosed at 2.4 mg weekly, representing the maximum studied dose for each component
Tirzepatide has shown more weight loss in studies, but both are effective
Designed to mimic the effects of the naturally occurring hormone GLP-1, Semaglutide holds promise not only for glycemic control but also for its remarkable impact on the individuals initial body weight
This is a common concern, and the clinical reality is that without a maintenance phase, some weight regain is possible because the bodys natural hunger signals will return
To date, there is still on-going research about Zepbound, but according to certain studies it may indeed proven as an effective treatment for obesity and diabetes
Vollset, J